Skinvisible, Inc, the developers of Invisicare, a patented polymer delivery system that enhances topical skincare products, and Cambrex Corporation, a leading provider of products and services to the pharmaceutical industry, announced that they have signed a joint marketing and development agreement.

The agreement provides for research and development into acne formulations based on Skinvisible's Invisicare technology and benzoyl peroxide (BPO) manufactured by Cambrex. In addition, the two companies will share marketing responsibilities for the products that are developed under this agreement.

"Invisicare is a technology that adds many advantages to active ingredients. Our recent developments with Cambrex's BPO in strengths of 2.5 per cent, 5 per cent and 10 per cent along with the BPO combination formulations we are developing, has given us a whole new series of acne products to license worldwide," said Terry Howlett, president and CEO of Skinvisible Pharmaceuticals.

"We have proven that we can control the release of active ingredients such as BPO with Invisicare and this can result in use of less active ingredient, less irritation and better efficacy. Additionally, Invisicare can hold ingredients on the skin allowing acne sufferers to benefit from the treatment for a longer period of time." He added, "We are confident that our collaboration with Cambrex will be beneficial to both parties as we have complementary ingredients that when combined, benefit from each other."

"Cambrex produces a high-grade benzoyl peroxide API that is made under cGMP and which has a Drug Master File (DMF)," said Steve Klosk, president and CEO of Cambrex Corporation. "This collaboration with Skinvisible will enable us to provide our clients with technology-enhanced delivery options for our BPO products. We are excited to have the opportunity to associate our API with Skinvisible's innovative technology. We foresee that this value-added approach is an advantage for our clients and acne patients."

Invisicare is Skinvisible's patented polymer delivery system that offers 'life-cycle management' and unique enhancements for topically delivered products.

Skinvisible Pharma is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products.

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including active pharmaceutical ingredients (API), advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals.